|
| ANTI-HUMAN RANTES Basic information |
Product Name: | ANTI-HUMAN RANTES | Synonyms: | ANTI-HUMAN CCL5;ANTI-HUMAN RANTES;ANTI-HUMAN RANTES MONOCLONAL ANTIBODY;ANTI-HUMAN RANTES POLYCLONAL ANTIBODY;ANTI-HUMAN REGULATED UPON ACTIVATION NORMAL T CELL EXPRESSED SEQUENCE;ANTI-HUMAN SIS-DELTA;ANTI-RANTES, HUMAN;ANTI-RANTES | CAS: | | MF: | | MW: | 0 | EINECS: | | Product Categories: | | Mol File: | Mol File | |
| ANTI-HUMAN RANTES Chemical Properties |
storage temp. | −20°C | form | lyophilized powder |
| ANTI-HUMAN RANTES Usage And Synthesis |
Uses | Anti-RANTES antibody may be used for immunoblotting at a working concentration of 0.1 μg/ml. For immunohistochemistry and immunofluorescence, a working concentration of 5-15 μg/ml may be used. The antibody is suitable for neutralization reactions (ND50 is 0.1-0.4 μg/ml). | General Description | RANTES (Regulated upon Activation, Normal T cell Expressed and Secreted; CCL5) is a chemokine that brings T cells, monocytes, eosinophils, NK cells, dendritic cells and mast cells to the site of infection or inflammation. RANTES has an unusual kinetic profile and is secreted 3-5 days after the activation of the T cells. It also exhibits antimicrobial activity by inducing the production of nitric oxide in macrophages. The main function of RANTES is mediated by CCR5, CCR1, CCR3 and other receptors. The expression of RANTES is regulated mainly by JAK/STAT and NF-κB pathways. Polymorphisms in the gene encoding RANTES are implicated in artherosclerosis, multiple sclerosis, HIV infection, diabetes, inflammatory diseases of the lung, renal disease and systemic lupus erythematosus. In addition, RANTES is a potential prognostic factor to track the progression of stage II breast cancer Anti-RANTES antibody specifically recognizes human RANTES. The antibody shows ~40% cross-reactivity with mouse RANTES and canine RANTES, ~20% cross-reactivity with cotton rat RANTES, and ~1% cross-reactivity with feline RANTES. |
| ANTI-HUMAN RANTES Preparation Products And Raw materials |
|